Approximately 75% of p53 mutations result in the loss of tumor-suppressive functions, allowing mutant p53 to actively contribute to cancer progression through mechanisms such as mTOR suppression, Cip1 inhibition, and NF-κB pathway activation (Marei et al., 2021; Aleksandrova et al., 2024). The gene discussed is TP53; the disease is neoplasm.